Coverage
-
September 23, 2015
The Third Circuit on Wednesday refused to reconsider, either by a panel or en banc, a ruling reviving an antitrust class action claiming GlaxoSmithKline PLC paid off Teva Pharmaceutical Industries Ltd. to delay its launch of generic Lamictal.
13 other articles on this case.
View all »